Business Context and Reporting Period
This Form 6-K filing by Prana Biotechnology Limited (ASX:PBT) covers the month of September 2009, specifically dated September 2, 2009. The registrant is a foreign private issuer based in Australia. The filing serves as a notice under Section 708A(5) of the Corporations Act regarding a new issue of securities and an application for quotation.
Key Financial Metrics and Capital Structure
The filing details a specific capital event rather than providing comprehensive financial statements (revenue, profit, or cash flow are not reported in this document).
- Ordinary Shares Issued: 54,500 new ordinary shares were issued.
- Options Issued: 80,000 unlisted options (PBTAF) were issued.
- Consideration: Both the shares and options were issued at nil consideration ($0).
- Total Quoted Securities: Following the issue, the total number of ordinary shares quoted on the ASX is 202,945,639.
- Unquoted Securities: The company holds various classes of unlisted options with exercise prices ranging from nil to AUD$0.50 and expiry dates between 2009 and 2014.
Material Changes
The primary material change is the increase in the company's share capital and option pool resulting from the exercise of options and issuance of new options under the Employee Incentive Scheme and Consulting Agreements. The new ordinary shares rank pari passu with existing ordinary shares. The new options are exercisable at nil consideration on or before October 31, 2010.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, or an outlook for future periods. It is a regulatory disclosure of a capital transaction. The document notes that the dividend policy remains unchanged. No specific risks or contingencies are detailed beyond standard regulatory warranties regarding the legality of the issue.
Investor Verification Checklist
- Verify the total diluted share count, noting the 54,500 new shares and the 80,000 new nil-cost options.
- Confirm the impact of the nil consideration issuance on existing shareholder dilution.
- Review the full schedule of unlisted options (PBTAK, PBTAW, PBTAA, etc.) to understand potential future dilution from the 2004 ASX Plan and 2004 US ADS Plan.
- Check subsequent filings for financial performance, as this 6-K contains no revenue or earnings data.